Research programme: Zika virus vaccine - Acuitas Therapeutics/University of Pennsylvania

Drug Profile

Research programme: Zika virus vaccine - Acuitas Therapeutics/University of Pennsylvania

Alternative Names: Pre-membrane and envelope glycoprotein mRNA-LNP; prM-E glycoprotein mRNA-LNP; Zika virus mRNA-LNP; Zika virus vaccine - Acuitas Therapeutics/University of Pennsylvania; ZIKV mRNA-LNP

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator Acuitas Therapeutics
  • Developer Acuitas Therapeutics; University of Pennsylvania
  • Class RNA vaccines; Zika virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Zika virus infection

Most Recent Events

  • 13 Feb 2017 Preclinical data in Zika virus infection presented at the 24th Conference on Retroviruses and Opportunistic Infections (CROI-2017)
  • 02 Feb 2017 Preclinical data in Zika virus infections released by Acuitas Therapeutics and the University of Pennsylvania
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top